Northwest Biotherapeutics Inc (NWBO)
0.4601
-0.01
(-2.54%)
USD |
OTCM |
Apr 24, 16:00
Northwest Biotherapeutics Enterprise Value: 586.17M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 586.17M |
| April 23, 2024 | 600.45M |
| April 22, 2024 | 609.97M |
| April 19, 2024 | 609.85M |
| April 18, 2024 | 645.55M |
| April 17, 2024 | 634.96M |
| April 16, 2024 | 640.20M |
| April 15, 2024 | 636.03M |
| April 12, 2024 | 657.45M |
| April 11, 2024 | 652.45M |
| April 10, 2024 | 654.95M |
| April 09, 2024 | 669.35M |
| April 08, 2024 | 677.47M |
| April 05, 2024 | 683.39M |
| April 04, 2024 | 687.44M |
| April 03, 2024 | 693.15M |
| April 02, 2024 | 689.58M |
| April 01, 2024 | 658.05M |
| March 28, 2024 | 656.26M |
| March 27, 2024 | 752.65M |
| March 26, 2024 | 670.54M |
| March 25, 2024 | 649.12M |
| March 22, 2024 | 613.48M |
| March 21, 2024 | 616.04M |
| March 20, 2024 | 619.37M |
| Date | Value |
|---|---|
| March 19, 2024 | 640.79M |
| March 18, 2024 | 656.26M |
| March 15, 2024 | 669.35M |
| March 14, 2024 | 669.35M |
| March 13, 2024 | 687.20M |
| March 12, 2024 | 705.05M |
| March 11, 2024 | 697.91M |
| March 08, 2024 | 713.38M |
| March 07, 2024 | 723.02M |
| March 06, 2024 | 724.80M |
| March 05, 2024 | 705.76M |
| March 04, 2024 | 727.42M |
| March 01, 2024 | 737.77M |
| February 29, 2024 | 690.77M |
| February 28, 2024 | 681.37M |
| February 27, 2024 | 679.82M |
| February 26, 2024 | 674.59M |
| February 23, 2024 | 686.93M |
| February 22, 2024 | 696.81M |
| February 21, 2024 | 698.10M |
| February 20, 2024 | 752.76M |
| February 16, 2024 | 699.74M |
| February 15, 2024 | 695.75M |
| February 14, 2024 | 713.26M |
| February 13, 2024 | 686.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
103.89M
Minimum
Mar 18 2020
1.873B
Maximum
May 05 2022
691.70M
Average
719.84M
Median
Dec 23 2021
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.284M |
| Palatin Technologies Inc | 18.43M |
| iBio Inc | 16.49M |
| Theriva Biologics Inc | -13.90M |
| Oragenics Inc | 3.306M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.92M |
| Revenue (Quarterly) | 0.445M |
| Total Expenses (Quarterly) | 15.59M |
| EPS Diluted (Quarterly) | -0.02 |
| Profit Margin (Quarterly) | -4.25K% |
| Earnings Yield | -13.04% |
| Normalized Earnings Yield | -12.74 |